Aardvark Therapeutics (AARD) reported a Q2 loss Wednesday of $0.66 per diluted share, narrowing from $1.37 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.60.

The company did not report any revenue for the quarter ended June 30.

As of June 30, the company said it had $141.8 million in cash, cash equivalents, and short-term investments, expected to fund operations into 2027.